A Quote by J. D. Vance

The regulatory approach of the Food and Drug Administration and the Patent and Trademark Office has driven up the costs of generic drugs. — © J. D. Vance
The regulatory approach of the Food and Drug Administration and the Patent and Trademark Office has driven up the costs of generic drugs.
The higher cost of getting a generic drug approved by regulators means that many old medicines don't face competitors. It's only after substantial price hikes that these drugs offer enough revenue to offset the rising generic entry costs, and start to entice competition.
That reminds me to remark, in passing, that the very first official thing I did, in my administration-and it was on the first day of it, too-was to start a patent office; for I knew that a country without a patent office and good patent laws was just a crab, and couldn't travel any way but sideways or backways.
One of the most powerful weapons in the Food and Drug Administration's arsenal is its ability to censure companies that promote drugs for unapproved uses.
Consider the clinicaltrials by which drugs are tested in human subjects.5 Before a new drug can enter the market, its manufacturer must sponsor clinicaltrials to show the Food and Drug Administration that the drug is safe and effective, usually as compared with a placebo or dummy pill. The results of all the trials (there may be many) are submitted to the FDA, and if one or two trials are positive—that is, they show effectiveness without serious risk—the drug is usually approved, even if all the other trials are negative.
The same drugs are way cheaper in Germany than in America because, obviously, if all sickness funds negotiate with the drug companies for a single price, then the market power of the sickness funds is fully used. So therefore you would expect the prices to be lower for the drugs in Germany, and this is exactly what you see, at least for non-generic drugs.
Lincoln said that the Patent Office adds the flame of interest to the light of creativity. And that is why we need to improve the effectiveness of our Patent Office.
We need to work on drug costs, and there's things we can work on on drug costs, especially Medicare Part D, to bring drug costs down.
"Drugs" are not necessarily narcotics. The narcotic is one type of drug and coffee is a drug... booze is a drug... many drugs.... They're all around us.
The under-funded and over-extended United States Patent and Trademark Office does not have the resources to adequately evaluate the burgeoning number of applications, and too many low-quality patents are being issued as a result.
Increasing patient access to more affordable, FDA-approved generic and biosimilar medicines is a proven and tested solution to lowering prescription drug costs.
Fast food may appear to be cheap food and, in the literal sense it often is, but that is because huge social and environmental costs are being excluded from the calculations. Any analysis of the real cost would have to look at such things as the rise in food-borne illnesses, the advent of new pathogens, antibiotic resistance from the overuse of drugs in animal feed, extensive water pollution from intensive agricultural systems and many other factors. These costs are not reflected in the price of fast food.
For all of life's discontents, according to the pharmaceutical industry, there is a drug and you should take it. Then for the side effects of that drug, then there's another drug, and so on. So we're all taking more drugs, and more expensive drugs.
The legalization of drugs, a proliferation of a public health approach to drug use and drug addition, a compassionate mental health system. And can we just say gender equality and the end of mass incarceration and the final shedding of the vestiges of a slave-based nation? Can we have that, too? Can I have it all?
A country without a patent office and good patent laws is just a crab, and can't travel any way but sideways and backways.
One dirty tactic big pharmaceutical companies use is keeping drug prices artificially high through anti-competitive conduct, such as paying competitors millions of dollars to stop them from creating generic drugs.
Regulators at the Food and Drug Administration have a tough job.
This site uses cookies to ensure you get the best experience. More info...
Got it!